BDRX: Biodexa Company Short-Term Debt

biodexapharma.com (BDRX) - corporate logo

Biodexa Pharmaceuticals (BDRX) develops treatments for orphan diseases, with the business's financial foundation relying on external funding and clinical trial results. Margin protection is secured through orphan drug designations and patents within the brain tumor targeted therapy segment. This price trend on GURU.Markets, where the indicator stands at 0.00, complements the profile of this bioengineering and targeted drug delivery innovator.

BDRX (Biodexa Pharma) Company Short-Term Debts history from 04/28/2023 to 10/30/2026

Analytical breakdowns and data insights for company Biodexa (BDRX)

- current quotes and average value forecast:
Price Chart Biodexa Pharma|BDRX - Fair Value Consensus
- market capitalization information:
Market Value Biodexa Pharmaceuticals PLC|BDRX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Biodexa Pharmaceuticals|BDRX - Book Capitalization|Market Capitalization to Book Value Ratio biodexapharma.com|BDRX - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Biodexa Pharmaceuticals|BDRX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Biodexa Pharma|BDRX - Company Debts|Debts to Book Capitalization Biodexa Pharmaceuticals PLC|BDRX - Long-Term Debt Volume|Company Short-Term Debt Biodexa Pharmaceuticals|Quick Ratio biodexapharma.com
- net income and valuation multiples indicators:
BDRX - Company Profit
Fundamental company valuation:biodexapharma.com (BDRX)
Flagship merchandise of Biodexa

For the long-term investor, the reliability of Biodexa Pharmaceuticals (BDRX) is determined by its ability to cover operating expenses amid a high dependency on clinical trial outcomes. By analyzing the volume of short-term liabilities, which aggregates all loans maturing within one year, one can assess the capital burn rate and the effectiveness of secondary offerings that support the current financial stability of the business against industry risks.

Competitors of Biodexa Pharmaceuticals

CVS - Company Short-Term Debt|Company Short-Term Loans and Borrowings MCK (McKesson Corp)|AmerisourceBergen (COR) - Company Short-Term Debt|Company Current Liabilities Cardinal Health Group|HSIC (Henry Schein, Inc.) - Company Short-Term Debts|Company Short-Term Debts prestigebrands.com|Company Short-Term Debts WGRX|Company Current Liabilities 111.com.cn YI|China Jo-Jo Drugstores Inc. - Company Current Liabilities|Universe Pharma (UPC) - Short-Term Debt|HK Pharma Digital - Company Short-Term Debts|BIMI: Company Short-Term Debt|CJJD: Company Short-Term Debts|WBA - Short-Term Debt Volume